Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 1
Several articles and news releases can be found in Yahoo Finance. But here is the beginning paragraphs of a Bloomberg article released today:
Medtronic Inc. (MDT)’s Infuse, designed to help bones heal after spinal surgery, works no better than a graft and carries side effects including an increased risk of cancer, two independent reviews found.
The studies published in the Annals of Internal Medicine may help doctors weigh when to recommend the product, used in more than 1 million patients. The $2.5 million review of Infuse was commissioned by Minneapolis-based Medtronic in 2011 after the product’s risk-benefit profile was called into question by research linking it to male sterility, infections and cancer.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.